SCHEMBL5137501

SCHEMBL5137501

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1ccc(Br)cc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
TSHR P16473 3/20 0.39
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP3A4 P08684 3/20 0.39
HPGD P15428 3/20 0.39
HSD17B10 Q99714 3/20 0.39
PDE4B Q07343 2/20 0.39
ATP4A P20648 2/20 0.39
ATP4B P51164 2/20 0.39
CNR2 P34972 1/20 0.39
CRHR1 P34998 2/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
HSD11B1 P28845 1/20 0.38
HDAC1 Q13547 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136527 0.97 C5AR1 (0.46) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5134969 0.95 C5AR1 (0.41) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5135043 0.93 C5AR1 (0.46) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5137962 0.93 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5134917 0.92 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5134997 0.91 C5AR1 (0.47) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5136887 0.90 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5135469 0.90 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5072228 0.90 C5AR1 (0.46) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5137489 0.89 C5AR1 (0.48) C5AR1TSHRKDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed